Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release

Laboratory Investigation

Volumn 92, Issue 12, 2012, Pages 1766-1776

  Ogawa, Masahito ^a,b,c   Suzuki, Jun Ichi ^b   Takayama, Kiyoshi ^d   Senbonmatsu, Takaaki ^e   Hirata, Yasunobu ^b   Nagai, Ryozo ^b   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^d NB Health Laboratory   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

infarction; inflammation; remodeling; renin angiotensin system

Indexed keywords

ALISKIREN; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY FUNCTION; MONONUCLEAR CELL; MOUSE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; TRANSGENIC MOUSE; UPREGULATION;

EID: 84870424256     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.136     Document Type: Article

References (26)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
2. Virzì GM, Corradi V, Panagiotou A, et al. ADPKD: prototype of cardiorenal syndrome type 4. Int J Nephrol 2010;2011:490795.
3. McCullough P. Prevention of cardiorenal syndromes. Contrib Nephrol 2010;165:101-111.
4. McCullough PA. Cardiorenal syndromes: pathophysiology to prevention. Int J Nephrol 2011;2011:762590.
5. McCullough PA, Ahmad A. Cardiorenal syndromes. World J Cardiol 2011;3:1-9.
6. Strauss M, Hall A. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-854.
7. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.
8. Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008;118:984-993.
9. Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117:3199-3205.
10. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011;32:1227-1234.
11. Westermann D, Riad A, Lettau O, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008;52:1068-1075.
12. Burney BO, Kalaitzidis RG, Bakris GL. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009;18:107-111.
13. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.
14. Fukamizu A, Sugimura K, Takimoto E, et al. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angioten-sinogen genes. J Biol Chem 1993;268:11617-11621.
15. Sugaya T, Nishimatsu S, Tanimoto K, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995;270:18719-18722.
16. Tapia E, Franco M, Sánchez-Lozada L, et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 2003;63:994-1002.
17. Shimazaki M, Nakamura K, Kii I, et al. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 2008;205: 295-303.
18. Harraz MM, Marden JJ, Zhou W, et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 2008;118:659-670.
19. Ogawa M, Suzuki J, Hishikari K, et al. Clarithromycin attenuates acute and chronic rejection via matrix metalloproteinase suppression in murine cardiac transplantation. J Am Coll Cardiol 2008;51: 1977-1985.
20. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996;29: 225-229.
21. Ogawa M, Suzuki J, Kosuge H, et al. The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation 2009;87:1645-1653.
22. Looi YH, Grieve DJ, Siva A, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 2008;51:319-325.
23. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900-907.
24. Ago T, Kuroda J, Pain J, et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 2010;106:1253-1264.
25. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003;108:2134-2140.
26. Kaikita K, Hayasaki T, Okuma T, et al. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol 2004;165:439-447.